Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kura Oncology

7.58
-0.0700-0.92%
Volume:1.05M
Turnover:7.94M
Market Cap:657.92M
PE:-3.36
High:7.65
Open:7.64
Low:7.47
Close:7.65
52wk High:21.57
52wk Low:5.41
Shares:86.80M
Float Shares:63.99M
Volume Ratio:0.55
T/O Rate:1.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2592
EPS(LYR):-2.0193
ROE:-51.11%
ROA:-22.93%
PB:2.15
PE(LYR):-3.75

Loading ...

Kura Oncology Announces Inducement Stock Option Grants for New Employees Under 2023 Plan

Reuters
·
Aug 04

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 04

Kura Oncology to Report Second Quarter 2025 Financial Results

GlobeNewswire
·
Jul 31

Kura Oncology reports inducement grants under Nasdaq listing rule

TIPRANKS
·
Jul 03

Kura Oncology Partners with Kyowa Kirin for Ziftomenib

TIPRANKS
·
Jul 01

Kura Oncology Inc. and Kyowa Kirin Enter Co-Promotion Agreement for Leukemia Treatment in the U.S

Reuters
·
Jul 01

Kura Oncology Price Target Maintained With a $36.00/Share by Wedbush

Dow Jones
·
Jun 20

Wedbush Keeps Their Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
Jun 20

TD Cowen Remains a Buy on Kura Oncology (KURA)

TIPRANKS
·
Jun 20

Optimistic Outlook on Kura Oncology: Promising Developments in AML Treatment with Ziftomenib

TIPRANKS
·
Jun 19

Kura Oncology Announces Positive Phase 1a/1b Trial Results

TIPRANKS
·
Jun 19

Kura Oncology Inc. Unveils Presentation on Ziftomenib for AML Treatment and Development Plans

Reuters
·
Jun 19

Kura Oncology (KURA) Gets a Buy from TD Cowen

TIPRANKS
·
Jun 13

Promising Clinical Trial Results and Future Prospects Justify Buy Rating for Kura Oncology

TIPRANKS
·
Jun 13

Kura Oncology Says Ziftomenib Study Achieves Complete Remission in Acute Myeloid Leukemia

MT Newswires Live
·
Jun 12

Barclays Reaffirms Their Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
Jun 10

Kura Oncology Stockholders Approve Equity Plan Amendment

TIPRANKS
·
Jun 07

Kura Oncology reports inducement grants under Nasdaq listing rule

TIPRANKS
·
Jun 06

BRIEF-Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Jun 06

Scotiabank Sticks to Their Hold Rating for Kura Oncology (KURA)

TIPRANKS
·
Jun 04